Abstract: An accurate prediction of progression is critically important in the management of non-muscle-invasive bladder cancer. At present, three risk models are widely known for prediction of the risk of tumor recurrence and progression of nonmuscle-invasive bladder cancer: the European Organization for Research and Treatment of Cancer, Club Urol ogico Español de Tratamiento Oncol ogico, and new European Organization for Research and Treatment of Cancer models. Bladder neck involvement has been shown to be one of the significant predictors for progression in non-muscleinvasive bladder cancer, and a new scoring model (Tokyo Medical and Dental University model) consisting of bladder neck involvement, tumor grade, and stage has been developed and externally validated. However, the predictive abilities of these models are still unsatisfactory, and more precise models are necessary for accurate individual prediction of prognosis. Until now, time-fixed analysis has been used for most studies predicting the prognosis and outcome of non-muscle-invasive bladder cancer patients. In order to predict progression more precisely, time-dependent models should be developed using multiple-event analytical techniques, as non-muscle-invasive bladder cancer often progresses to muscle-invasive bladder cancer after multiple recurrences and changes in tumor characteristics over a long natural history. Integration of molecular markers is also a promising approach. A validated model that accurately predicts the risk of progression would help urologists and patients decide whether and when to choose radical cystectomy on an individual basis.
Introduction
Urothelial carcinoma of the urinary bladder is one of the most common genitourinary malignancies. In 2009 in Japan, bladder cancer was the eighth most common cancer in men and the 17th most common cancer in women. 1 Approximately 70-75% of newly diagnosed bladder cancers are classified as NMIBC (pTa, pT1 and pTis). 2, 3 NMIBC is a heterogeneous population of tumors. Despite its high recurrence rate (40-80%), NMIBC generally shows a favorable prognosis. However, progression to muscle-invasive and/or metastatic disease occurs in approximately 15% of patients, and once patients develop progression, their prognoses are generally unfavorable. 4 For example, in a study comparing the prognosis of primary and progressive MIBC, the 3-year bladder cancer-specific survival was 67% in the primary group and 37% in the progressive group (log-rank P = 0.0015). The researchers concluded that patients with MIBC and a history of NMIBC have a worse prognosis than do patients with primary MIBC. Thus, an accurate prediction of progression is critically important in the management of NMIBC. Additionally, radical cystectomy needs to be considered in some high-risk NMIBC patients.
Despite the existence of multiple definitions and formulae for identifying high-risk patients, several studies have shown that the most significant prognostic factors usable by physicians for identifying the patients at greatest risk of developing MIBC are tumor grade and stage. and response to BCG. [9] [10] [11] [12] Therefore, risk classification models consisting of various factors are expected to improve the predictive accuracy. At present, three risk models are widely known for prediction of the risk of tumor recurrence and progression of NMIBC: the EORTC risk tables, 12 the CUETO scoring model 13 and the new EORTC model. 14 Some previous studies, including ours, have shown that another predictor of tumor recurrence or progression is tumor location, especially those with BNI. 6, 7, [15] [16] [17] In the present review, we provide an overview of the models used to predict progression in NMIBC of pTa and pT1 stages. Their limitations and novel approaches are then discussed, with a special focus on the importance of tumor location.
Risk factors for progression in NMIBC Histological grading
Histological grade is one of the strongest predictors for tumor progression of NMIBC. At present, two different classification systems are used for NIMBC grading: the WHO 1973 and 2004 grading systems. The 1973 WHO classification separates papillary urothelial carcinomas into three categories (grades 1-3). Despite being widely used for >30 years, the 1973 WHO grading system has been consistently criticized for not having defined distinct cut-off points among the three tumor grades.
In 2004, the WHO published a new histological classification of urothelial carcinomas, which provides a different patient stratification between individual categories than that of the older 1973 WHO classification. 18, 19 The WHO 2004 system's new category, PUNLMP, allowed for physicians to avoid the use of the term carcinoma when classifying tumors with a low probability of progression, but that are not entirely benign. Diagnoses of non-invasive papillary urothelial carcinomas in the WHO 1973 system could now be separated into three categories: (i) designated PUNLMP; (ii) low-grade carcinoma; and (iii) high-grade carcinoma. As noted in its introduction, the 2004 WHO system would provide detailed histological criteria for the diagnosis of papillary urothelial neoplasms, and this feature was designed to improve diagnostic reproducibility among pathologists. 1, 2 or 3) . 25 At present, the WHO 2004 system has not yet been fully incorporated into the following prognostic models.
Pathological stage
The overall rate of recurrence for NMIBC is 40-80%, and the overall rate of progression is approximately 15%. However, pTa tumors, most of which are low grade, rarely progress to muscle-invasive disease, although their recurrence rate is high.
In contrast, pT1 tumors represent a different entity. Some respond to conservative measures and behave in a non-lethal fashion, whereas others are more aggressive and tend to progress to muscle invasion and even metastasis. Many pT1 tumors are high grade, with a higher potential for progression and death. When treated with TURBT alone, pT1 tumors have a high risk of progression to muscle invasion. Some studies have reported that pT1G3 tumors progress in >50% of cases; deaths from disease occur in 25% of patients in the first 5 years, and in 10% of patients between 5 to 15 years. 26 Primary bladder CIS (pTis) is apparently shown to be likely to progress to muscle invasion, and treatment of CIS differs from that of papillary transitional NMIBCs (pTa and pT1). However, CIS is mostly concomitant with papillary NMIBCs, and results differed among studies as to whether concomitant CIS increased progression. In some studies, whether the cancer is primary or concomitant CIS, 50% progress to muscle invasion and 20% of patients will ultimately die of metastatic disease if they are treated conservatively. 5, 27 However, in other studies, including ours, concomitant CIS was not significant for progression. 6, 7, 28, 29 
Tumor location
As previously mentioned, prognostic factors in patients with NMIBC have been widely studied. To date, a much smaller number of studies have selected tumor location as a variable. Several previous studies have shown that tumor location, especially in the bladder neck and/or trigone, is associated with worse outcomes in NMIBC. 6, 7, 15, 16 We previously reported that BNI as well as tumor grade and stage was an independent risk factor for progression in primary NMIBC in three independent cohorts: retrospective and prospective cohorts at a single institution (TMDU), 6, 7 and a large multicenter retrospective cohort. 30 Other groups have also reported that BNI was associated with tumor recurrence or progression in NMIBC. [15] [16] [17] For instance, Vukomanovic et al. investigated the prognostic value of tumor location in high-grade NMIBC, and reported that tumors in the bladder neck had a higher risk of recurrence after intravesical BCG therapy. 17 At present, it is unclear why tumors in the bladder neck are likely to progress. It might be due to incomplete transurethral resection and the limited contact time of the intravesical agent with the bladder mucosa. 17 Alternatively, particular histological and anatomical features of the bladder neck could also contribute to these worse outcomes. Bladder neck and/or trigone tumors close to the vascular bed of the bladder neck might permit easier access to vascular channels and/or prostatic stroma. Furthermore, the lamina propria in the bladder neck and trigone regions is extremely thin, and the muscularis propria is quite close to the surface, both of which might facilitate progression. 31 Previous studies have suggested that bladder neck tumors are likely to accompany prostatic urothelial carcinoma. Case in point: in a study of 235 patients undergoing radical cystoprostatectomy for bladder cancer, prostatic urothelial carcinoma was found in 77 of these patients (33%), 49 of whom (64%) also showed prostatic stromal invasion. Bladder neck and trigone bladder tumor location (P < 0.001) and CIS (P < 0.001) were also found to be strongly associated with prostatic urothelial carcinoma. 32 Additionally, the incidence of prostatic urothelial carcinoma in NMIBC patients was higher than in MIBC patients: 41% (20/49 patients) and 31% (57/186 patients), respectively. In our previous study, 7 33% (10/30) of patients with BNI underwent prostatic urethral biopsy, yet prostatic urethral carcinoma was found in none of these cases.
Other factors
Factors other than histological grade and stage have not been established as risk factors for progression in NMIBC. In some studies, tumor multiplicity, size, shape, prior recurrence rate, lymphovascular invasion and histological type have been reported to be important in NMIBC progression. 5, 12, 13, 33 However, their prognostic impacts are not consistent. For example, only histological grade and stage were significant for progression in a study of 1812 patients who received maintenance BCG.
14 In another study, only tumor shape and grade were associated with progression-free survival. 29 Can BCG immunotherapy prevent progression in NMIBC?
Intravesical BCG immunotherapy is superior to intravesical chemotherapy for preventing the recurrence of NMIBC, which has been confirmed by a number of meta-analyses. 34 However, it remains unclear whether BCG can also prevent its progression.
Some meta-analyses of aggregate data reported that BCG therapy prevents, or at least delays, the risk of tumor progression (Table 1) . [34] [35] [36] For example, a meta-analysis evaluated data from 4863 patients enrolled in 24 randomized controlled trials. Some form of BCG maintenance therapy was used in 20 of the trials. During a median follow-up period of 2.5 years, 260 out of 2658 patients (9.8%) treated with BCG developed tumor progression, whereas 304 out of 2205 (13.8%) in the control groups did as well (TURBT alone, TURBT and intravesical chemotherapy or TURBT and other immunotherapy). The size of the reduction was similar in patients with Ta, T1 papillary tumors and in those with CIS. 36 Another recent randomized controlled trial has shown that patients treated with BCG developed significantly fewer distant metastases, and had better overall-and disease-specific survival rates than did those with epirubicin, although progression rates did not differ between the groups. 37 In contrast, there is a meta-analysis of individual patient data that did not show any statistically significant difference between MMC and BCG for progression, survival or cause of death (Table 1) . 38 The conflicting results among these studies can be explained by differing definitions of progression, patient characteristics, methodology and statistical power. However, most studies showed a reduction in the risk of progression in highand intermediate-risk tumors if patients were treated with BCG induction coupled with maintenance therapy.
Therefore, many researchers assume that BCG certainly reduces the risk of progression in NMIBC patients. However, it is also true that this effect is not satisfactory: BCG reduces the progression rate by just 30%. 39 Radical cystectomy should be considered for some high-risk NMIBC patients. To identify these patients, an accurate method of predicting progression is critically important in the management of patients with NMIBC.
EORTC risk tables/CUETO scoring model/new EORTC risk groups
Currently, three risk models are widely known for the prediction of the risk of tumor recurrence and progression of NMIBC: the EORTC, CUETO and new EORTC models ( Table 2) .
The EORTC Genito-Urinary Cancer Group developed a scoring system and risk tables to predict the probabilities of disease recurrence and progression. 12 The basis for the EORTC risk tables are individual patient data from 2596 patients diagnosed with pTa, pT1 tumors, who were randomized into seven EORTC trials. The scoring system is based on the six most significant clinical and pathological factors (tumor grade, T stage, tumor size, prior recurrence rate, presence of concomitant CIS and number of tumors) with different weights, which are shown in Table 2 . A total of 78% of patients received intravesical treatment, mostly chemotherapy. However, the data were limited by the fact that no patients underwent a second TURBT (currently a standard procedure in urological practice for T1 tumors) and that a low number of patients received BCG, all of whom were without a maintenance schedule.
The CUETO (Spanish Urological Oncology Group) developed a scoring model for BCG-treated patients that predicts the risks of recurrence and progression. 13 The CUETO model is based on an analysis of 1062 patients from four CUETO trials that compared different intravesical BCG treatments. Patients received 12 instillations over a 5-to 6-month period. The scoring system is based on the evaluation of seven prognostic factors (tumor grade, T stage, age, sex, prior recurrence status, number of tumors and presence of concomitant CIS) with different weights (Table 2 ). The study was limited by the fact that a second TURBT or BCG maintenance was not carried out, which could have an impact on the outcomes.
Both the EORTC risk table and the CUETO scoring model were developed based on the data of clinical trials, and recent multi-institutional validation studies have reported their insufficient predictive abilities. 40, 41 Lammers et al. reported that these models provided a low positive predictive value for progression, especially in high-grade disease (EORTC: 21%, CUETO: 24%). 40 Xylinas et al. externally validated the utility of both models using a multicenter cohort of 4689 patients with NMIBC. 41 They reported that the EORTC risk tables and the CUETO scoring model showed poor discrimination for both recurrence (c-indices 0.597 and 0.523, respectively) and progression (c-indices 0.662 and 0.616, respectively). Both models overestimated the risk of progression, especially in high-risk NMIBC patients. Furthermore, because both models use a number of weighted variables and their scoring systems are relatively complicated, they might be difficult to use in a clinical setting.
In 2016, EORTC developed and validated new EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in NMIBC patients treated with maintenance BCG.
14 Using data from 1812 intermediate-and high-risk patients without CIS who were treated with 1-3 years of maintenance BCG in two EORTC trials, they found that statistically significant prognostic factors were prior recurrence rate and the number of tumors for recurrence, and tumor stage and grade for progression and death due to bladder cancer. For progression, patients were divided into four groups: pTaG1, pTaG2 or pT1G1, pTaG3 or pT1G2 and pT1G3. However, it is again insufficient to make an accurate prediction of outcomes using just two factors, and its predictive abilities were determined to be unsatisfactory. The c-indexes for progression in the training and validation data sets were 0.72 and 0.64, respectively. Other limitations of this study include a lack of second TURBT in high-risk patients and exclusion of patients with CIS.
TMDU model that includes tumor stage, grade and bladder neck involvement
Based on our data that BNI is one of the risk factors for progression, we have developed and validated a simple predictive scoring model (TMDU model) for progression, consisting of tumor grade, stage and BNI, all of which were scored as 1 point, contributing equally to the model. 6, 7 In 1998, using a retrospective cohort of primary NMIBC at TMDU, we reported that BNI, as well as tumor grade and stage, were all independent factors for progression. 6 In this study, patients with tumors located in the prostatic urethra and primary CIS were excluded. Over a median follow-up period of 7.7 years, progression occurred in 28 (10.1%) of 277 patients. Additionally, multivariate analysis showed that independent factors for progression included BNI (HR 4.85, P < 0.001), tumor grade (grade 3 vs 1-2, HR 2.80, P = 0.016) and stage (pT1 vs pTa, HR 2.07, P = 0.003). Based on these findings, we developed a simple scoring model to predict progression that consisted of three variables: tumor stage, histological grade and BNI. In this model, these three progression factors were scored as 1 point equivalently, and the patients were divided into three groups (scores of 0, 1 and 2-3). The progression rates of these three groups were clearly differentiated. 6 Groups having none, one, or two or three factors showed 5-year progression rates of 0.8, 4.6 and 27.5%, respectively.
In 2014, using a prospective cohort of 297 patients with primary NMIBC without tumors located in the prostatic urethra or primary CIS at TMDU, we prospectively validated that stage T1 (HR 6.91, P = 0.001), grade 3 (HR 9.45, P < 0.001) and BNI (HR 11.75, P < 0.001) were all independent factors for progression. 7 Progression rates were clearly differentiated (P < 0.0001) when the patients were separated into three groups based on their scores (0, 1 or 2-3). These groups showed 5-year progression rates of 0, 8.7 and 34.1%, respectively. Our TMDU model's predictive ability was confirmed with a c-index of 0.80, which was superior to the c-index value of 0.74 for the two-factor (tumor grade and stage) model. In our study, if tumors were pathologically diagnosed as T1 at the initial TUR, a second TURBT was prescribed. Throughout the study period, the 297 patients underwent a total of 528 TURBT procedures (297 times for primary tumors and 231 times for recurrent tumors). There were 108 cases of pT1 tumors, and of these, 56 (52%) were treated with a second TURBT. In these patients, no MIBCs were found at the second TURBT. During this period, a total of 41 patients (14%) underwent instillations of BCG with or without a maintenance schedule.
In 2015, using a large multicenter retrospective cohort, we externally validated the impact of BNI on progression in NMIBC, and compared the prediction ability of our TMDU model with those of the EORTC risk tables and the CUETO model. 30 Enrollment included 1335 Japanese patients who had undergone TURBT for primary bladder tumors at 11 Japanese institutions, but which did not include TMDU, between 2006 and 2010. Additionally, these patients were pathologically diagnosed with Ta and T1 NMIBC. Once more, we excluded patients with primary CIS and those with tumors that were positioned in the prostate urethra. We found that 64 patients (4.8%) progressed over a median follow-up period of 48 months. Multivariate analysis again identified the independent predictors of progression as tumor grade (HR 2.40, P = 0.0012), stage (HR 2.69, P = 0.0008) and BNI (HR 1.82, P = 0.0315). Significantly different progression rates (P < 0.0001) were found when the patients were separated into three groups based on their TMDU scores (0, 1 or 2-3 points). The c-index of the TMDU model was 0.70, which was 0.71 in the EORTC risk tables and 0.72 in the CUETO model.
We believe that our TMDU scoring model, which incorporates BNI, can be easily used to both effectively estimate progression risk, and to establish the appropriate adjuvant treatment and follow-up procedures for patients on an individual basis.
Time-fixed and time-dependent models NMIBC often progresses to MIBC after multiple recurrences, and NMIBCs differ in terms of their tumor characteristics, including histological grade, T stage, tumor number, tumor diameter and tumor location in each recurrence. Given this aspect of NMIBC, multiple-event analytical techniques should be used, because time-dependent covariate analysis is more accurate than time-fixed analysis, the latter of which is used for most studies predicting the prognosis and outcome of NMIBC patients. 33, 42 We recently evaluated the prognostic role of voided urine cytology in 326 patients with pTa-1 NIMBC who underwent 597 TURBTs between 2000 and 2010. 42 During a median follow-up period of 46 months, positive voided urine cytology was independently associated with disease progression and cancer-specific death in both time-dependent and timefixed models. The tumor location was not included as a variable in this study. In our preliminary analyses using a timedependent model, BNI was a significant predictor of both recurrence and progression. 43 
Conclusions
Prognostic and prediction models with high discriminative accuracy might help facilitate the decision-making process and potentially improve clinical outcomes for NMIBC patients. At present, three risk models are widely known for the prediction of the risk of tumor recurrence and progression of NMIBC: the EORTC, CUETO and new EORTC models. In daily practice, urologists use these models to predict prognosis and guide treatment for patients. We have shown that BNI is one of the significant predictors for progression in NMIBC patients, and we have developed and externally validated a new scoring model (TMDU model) consisting of BNI, tumor grade and stage to predict progression. The TMDU model is easy to use and enables the physician to classify primary NMIBC patients into three groups with clearly different progression rates. We believe that it is worth comparing the predictive ability of our model with those of the EORTC, CUETO and new EORTC models in a prospective fashion. However, it is also true that predictive abilities of these models are still not satisfactory, and more precise models are necessary for individual prediction of prognosis.
To date, time-fixed analysis has been used for most studies that predict the prognosis and outcome of NMIBC patients. In order to predict progression more precisely, time-dependent models should be developed using multiple-event analytical techniques because NMIBC often progresses to MIBC after multiple recurrences and changes in tumor characteristics over a long natural history.
Integration of molecular markers would be a promising approach for improving prediction. 44 Recently, a number of molecular subtype classifications of bladder cancer have been proposed. 45 There is a study suggesting that classification of stage T1 urothelial carcinoma into molecular subtypes can improve the identification of patients with progressing tumors. 46 In this study, 167 primary stage T1 bladder urothelial carcinomas were characterized by immunohistochemistry, and classified into the molecular subtypes urobasal (32%), genomically unstable (58%) and squamous-cell carcinomalike (10%). The risk of progression was low for urobasal tumors and high for genomically unstable/squamous-cell carcinoma-like tumors. However, the value of molecular markers over clinicopathological indexes is still being questioned, and their clinical use is limited. A validated model that accurately predicts the risk of progression would help urologists and patients make the difficult choice of whether and when to choose radical cystectomy on an individual basis.
Editorial Comment
Editorial Comment to Prediction models for progression of non-muscle-invasive bladder cancer: A review Although non-muscle-invasive bladder cancer (NMIBC) has a good prognosis with a transurethral resection of the bladder tumor (TURBT), it has a high recurrence rate after treatment. In particular, in some cases, with a T1 tumor or carcinoma in situ (CIS), the tumor advances to the muscle as an invasive and metastatic tumor. It is important to control the progression of NMIBC because of a poor prognosis in patients with metastatic bladder cancer. Intravesical therapy is often carried out after TURBT, and bacillus Calmette-Gu erin (BCG) is usually used for the treatment of high-risk tumors, such as T1 tumors and CIS. However, a 30% reduction rate of tumor progression by BCG therapy is not sufficient, and it is important to select the patients who should receive radical cystectomy. Models for the decision to treat patients with intravesical therapy after TURBT and predictions of recurrence/progression after adjuvant therapy are required.
In this review, Fujii shows that historical grading, pathological stage, tumor location, multiplicity, size, shape, prior recurrence rate, lymphovascular invasion and histological type are risk factors for the progression of NMIBC according to previous reports and the author's research. 1 The author introduces three major predictive models: (i) European Organization for Research and Treatment of Cancer risk tables for the probabilities of recurrence and progression after TURBT; 2 (ii) a Spanish Urological Club for Oncological Treatment scoring model for the risk of recurrence and progression after BCG therapy; 3 and (iii) new European Organization for Research and Treatment of Cancer risk groups for recurrence, progression, and disease-specific and overall survival after the maintenance of BCG. 4 The author also suggests the limitations of the three models: the first two models are relatively complicated by a number of variables, and the third model is unsatisfactory because it uses only two factors. The ideal risk model is definitely a simple and accurate predictor to be used for the treatment decision.
The Tokyo Medical and Dental University model, which predicts the risk of progression, is classified by three factors: (i) tumor grade; (ii) stage; and (iii) bladder neck invasion in a patient without tumors located in the prostatic urethra and primary CIS. 5 Based on the results of the prospective cohort and multicenter retrospective cohort for external validation, the author suggests that the Tokyo Medical and Dental University model adequately predicts the risk compared with the European Organization for Research and Treatment of Cancer risk
